- Home
- Publications
- Publication Search
- Publication Details
Title
Introduction to checkpoint inhibitors and cancer immunotherapy
Authors
Keywords
-
Journal
IMMUNOLOGICAL REVIEWS
Volume 276, Issue 1, Pages 5-8
Publisher
Wiley
Online
2017-03-04
DOI
10.1111/imr.12531
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma
- (2017) Liliana E. Lucca et al. IMMUNOLOGICAL REVIEWS
- Viewing Siglecs through the lens of tumor immunology
- (2017) Isabella Fraschilla et al. IMMUNOLOGICAL REVIEWS
- The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3
- (2017) Murali Janakiram et al. IMMUNOLOGICAL REVIEWS
- TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy
- (2017) Yemsratch T. Akalu et al. IMMUNOLOGICAL REVIEWS
- Immunoregulatory functions of VISTA
- (2017) Elizabeth C. Nowak et al. IMMUNOLOGICAL REVIEWS
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
- (2017) William C. Dougall et al. IMMUNOLOGICAL REVIEWS
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
- (2015) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search